FDA Approves Fingolimod as First-Line Treatment for Relapsing Forms of MS
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Approves Fingolimod as First-Line Treatment for Relapsing Forms of MS

NEW YORK -- September 22, 2010 -- The US Food and Drug Administration (FDA) has approved fingolimod 0.5 mg (Gilenya) as first-line treatment for relapsing forms of multiple sclerosis.

Fingolimod reduces the frequency of MS relapses and helps slow the build-up of some of the physical problems caused by MS. In clinical trials, fingolimod has a well-studied safety and tolerability profile, which has been characterised in over 2,600 patients in clinical trials, some of whom are in their seventh year of treatment, with more than 4,500 patient years of experience.

The approval was based on the largest clinical trial program ever submitted to date to the FDA for the MS drug and included combined data from clinical studies showing significant efficacy in reducing relapses, the risk of disability progression, and the number of brain lesions detected by magnetic resonance imaging (MRI).

SOURCE: Novartis

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities